Plain-English translation of NCT05270733 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether researchers can predict how well psoriasis patients will respond to biologic medications by looking at genes in their skin cells. You'll receive two different medications— first, then either guselkumab or risankizumab—and researchers will study your skin to understand why some patients improve with one treatment while others don't.
Not all psoriasis patients respond equally to the same biologic treatments. By understanding the genetic differences in skin between people who improve and those who don't, doctors hope to eventually predict which medication will work best for each patient before they start treatment.
You likely qualify if…
You likely don't qualify if…
You'll receive injections of the first medication at weeks 0 and 4, then switch to one of two other medications also given as injections at weeks 0 and 4 of the next phase. Throughout the 8-week study, researchers will take skin samples and measure how much your psoriasis improves. The study involves regular clinic visits where doctors will examine your skin and collect genetic information to help them understand your response to treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States